These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. Williams AC; Ramsden DB J Clin Neurosci; 2005 Jan; 12(1):6-11. PubMed ID: 15639403 [TBL] [Abstract][Full Text] [Related]
5. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. Parsons RB; Smith ML; Williams AC; Waring RH; Ramsden DB J Neuropathol Exp Neurol; 2002 Feb; 61(2):111-24. PubMed ID: 11853016 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease: the first common neurological disease due to auto-intoxication? Williams AC; Cartwright LS; Ramsden DB QJM; 2005 Mar; 98(3):215-26. PubMed ID: 15728403 [TBL] [Abstract][Full Text] [Related]
10. A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase. van Haren MJ; Sastre Toraño J; Sartini D; Emanuelli M; Parsons RB; Martin NI Biochemistry; 2016 Sep; 55(37):5307-15. PubMed ID: 27570878 [TBL] [Abstract][Full Text] [Related]
11. Nicotinamide-N-methyltransferase controls behavior, neurodegeneration and lifespan by regulating neuronal autophagy. Schmeisser K; Parker JA PLoS Genet; 2018 Sep; 14(9):e1007561. PubMed ID: 30192747 [TBL] [Abstract][Full Text] [Related]
12. Nicotinamide N-methyltransferase catalyses the N-methylation of the endogenous β-carboline norharman: evidence for a novel detoxification pathway. Thomas MG; Sartini D; Emanuelli M; van Haren MJ; Martin NI; Mountford DM; Barlow DJ; Klamt F; Ramsden DB; Reza M; Parsons RB Biochem J; 2016 Oct; 473(19):3253-67. PubMed ID: 27389312 [TBL] [Abstract][Full Text] [Related]
13. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity. Neelakantan H; Vance V; Wang HL; McHardy SF; Watowich SJ Biochemistry; 2017 Feb; 56(6):824-832. PubMed ID: 28121423 [TBL] [Abstract][Full Text] [Related]
14. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Parsons RB; Smith SW; Waring RH; Williams AC; Ramsden DB Neurosci Lett; 2003 May; 342(1-2):13-6. PubMed ID: 12727306 [TBL] [Abstract][Full Text] [Related]
15. The kinetic analysis of the N-methylation of 4-phenylpyridine by nicotinamide N-methyltransferase: Evidence for a novel mechanism of substrate inhibition. van Haren MJ; Thomas MG; Sartini D; Barlow DJ; Ramsden DB; Emanuelli M; Klamt F; Martin NI; Parsons RB Int J Biochem Cell Biol; 2018 May; 98():127-136. PubMed ID: 29549048 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186 [TBL] [Abstract][Full Text] [Related]
18. Nicotinamide N-methyltransferase increases complex I activity in SH-SY5Y cells via sirtuin 3. Liu KY; Mistry RJ; Aguirre CA; Fasouli ES; Thomas MG; Klamt F; Ramsden DB; Parsons RB Biochem Biophys Res Commun; 2015 Nov; 467(3):491-6. PubMed ID: 26456643 [TBL] [Abstract][Full Text] [Related]
19. N-methyl(R)salsolinol and a neutral N-methyltransferase as pathogenic factors in Parkinson's disease. Maruyama W; Strolin-Benedetti M; Naoi M Neurobiology (Bp); 2000; 8(1):55-68. PubMed ID: 11008878 [TBL] [Abstract][Full Text] [Related]